📰 Aruvant Sciences News
Page 2 - Aruvant Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aruvant Sciences. Real-time updates on events, politics, business and more.
October 19, 2022
/PRNewswire/ -- The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector,...
October 13, 2022
Plus, Passage Bio has a new CEO, Beth Lawrence is leaving PSL, one Philly company is chosen for a national accelerator and another wins a national contest.
October 12, 2022
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
October 10, 2022
PHILADELPHIA, Oct. 10, 2022 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced... | October 10, 2022
June 10, 2022
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that Michael W. Kent, M.D.,...
May 12, 2022
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that data demonstrating the...
April 19, 2022
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that the company will...
March 3, 2022
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene...
January 20, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
January 20, 2022
NEW YORK and BASEL, Switzerland, Jan. 20, 2022 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and comme...